TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
-20.68%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$733M
AUM Growth
+$733M
(-28%)
Cap. Flow
-$16.4M
Cap. Flow
% of AUM
-2.24%
Top 10 Holdings %
Top 10 Hldgs %
55.3%
Holding
38
New
–
Increased
2
Reduced
3
Closed
1
Top Buys
| 1 |
Tyra Biosciences
TYRA
|
$8.45M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$4.6M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$19.6M |
| 2 |
Keros Therapeutics
KROS
|
$8.71M |
| 3 |
Disc Medicine
IRON
|
$1.08M |
| 4 |
RAPT Therapeutics
RAPT
|
$55K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
THRD
26
DELISTED
Third Harmonic Bio
THRD
| $8.69M | 1.19% |
2,505,424
| – | – |
|
|
SLN
27
Silence Therapeutics
SLN
$227M
| $8.55M | 1.17% |
3,033,560
| – | – |
|
28
Adverum Biotechnologies
ADVM
$64.6M
| $7.85M | 1.07% |
1,796,482
| – | – |
|
29
VistaGen Therapeutics
VTGN
$102M
| $6.69M | 0.91% |
2,676,580
| – | – |
|
|
JBIO
30
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $5.62M | 0.77% |
2,240,809
| – | – |
|
31
Entrada Therapeutics
TRDA
$208M
| $5.29M | 0.72% |
584,955
| – | – |
|
|
MBX
32
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $4.8M | 0.65% |
650,000
| – | – |
|
33
Avalo Therapeutics
AVTX
$122M
| $3.87M | 0.53% |
483,000
| – | – |
|
34
Kodiak Sciences
KOD
$478M
| $3.21M | 0.44% |
1,145,538
| – | – |
|
35
Nektar Therapeutics
NKTR
$568M
| $2.72M | 0.37% |
4,000,000
| – | – |
|
36
Ventyx Biosciences
VTYX
$171M
| $364K | 0.05% |
316,195
| – | – |
|
37
Cabaletta Bio
CABA
$133M
| $120K | 0.02% |
86,795
| – | – |
|
|
38
Keros Therapeutics
KROS
$618M
| – | – |
-550,000
| Closed | -$8.71M |
|